This study intends to gather information on HAE attack symptoms, how often the attacks occur, and the number of times treatment is required to manage the attacks in Korean people over a period of up to 11 months. The main aims of this study are the following: * To describe the patterns of HAE attacks, including how often they occur, where they happen in the body, how severe they are, the time between attacks, and any warning signs that appear before an attack. * To assess how HAE is treated, particularly looking at how on-demand treatments are used during HAE attacks. * To learn about the people who suffer from HAE attacks (e.g. age, gender, for how long they have been suffering from HAE, and if they use danazol to manage HAE). In this study, already existing data will be collected and reviewed from a mobile application called "MyHAE Story". The study will only review data collected as part of the clinical routine practice. The study will not impact the standard medical care and treatment of participants.
Study Type
OBSERVATIONAL
Enrollment
19
This is a non-interventional study.
Seoul National University Hospital
Seoul, South Korea
HAE Attack Rate
The HAE attack rate will be calculated as a per participant per month (PPPM) rate. The PPPM rate will be calculated by dividing the total number of attacks reported per each HAE participant during their observation periods by their duration of observation periods in months.
Time frame: Up to 11 months
Percentage of Participants With HAE Attack Based on Location
Number of participants with HAE attack based on anatomical location (face, throat, arm, hand, abdomen, genital, leg, foot) will be evaluated.
Time frame: Up to 11 months
Percentage of Participants With HAE Attack Based on Attack Severity
The HAE attack based on severity will be determined using following definitions: mild (temporarily feels somewhat uncomfortable, swelling is alleviated within 48 hours), moderate (slight disruption in daily life), severe (symptoms that make it impossible to carry out daily life).
Time frame: Up to 11 months
Average Time Interval Between HAE Attacks in Days
Time frame: Up to 11 months
Percentage of Participants With Prodromal Symptom
The presence of prodromal symptoms among participants, a response of "No" indicates the absence of any symptoms and a response of "Yes" suggests the presence of one or more symptoms from the following list will be reported: tight and stinging feeling in the skin, anxiety, nausea, sudden emotional changes, non-pruritic rash, severe fatigue, or other symptoms.
Time frame: Up to 11 months
Icatibant-treated HAE Attack Rate
The icatibant-treated HAE attack rate will be calculated as a PPPM rate. The PPPM rate will be calculated by dividing the total number of icatibant-treated attacks reported per each HAE participant during their observation periods by their duration of observation periods in months.
Time frame: Up to 11 months
Percentage of Icatibant-Treated HAE Attacks Among All HAE Attacks
Time frame: Up to 11 months
Number of HAE Attacks Categorized Based on the Icatibant Administration in a Single Attack
The number of icatibant administration in a single attack will be reported as either none, once, or twice.
Time frame: Up to 11 months
Number of Participants Categorized Based on Demographic Characteristics
Number of participants will be reported by their demographic characteristics (age, sex, disease duration and baseline danazol use).
Time frame: At Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.